Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 11/20 | 0.83 |
| ▸ | GLA | P06280 | 1/20 | 0.78 |
| ▸ | GAA | P10253 | 1/20 | 0.78 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | SNCA | P37840 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6984320 | 0.93 | APP (0.72) | APPGLAGAASULT1A1KDM4E | |
| SCHEMBL26017584 | 0.92 | APP (0.76) | APPGLAGAASULT1A1SNCA | |
| SCHEMBL1572797 | 0.91 | APP (0.74) | APPGLAGAASULT1A1KDM4E | |
| SCHEMBL21752042 | 0.91 | APP (0.74) | APPGLAGAASULT1A1KDM4E | |
| SCHEMBL12974045 | 0.91 | APP (1.00) | APPGLAGAASULT1A1KDM4E | |
| SCHEMBL23766560 | 0.91 | APP (0.74) | APPGLAGAASULT1A1KDM4E | |
| SCHEMBL4801119 | 0.91 | SULT1A1 (0.84) | APPGLAGAASULT1A1SMN1; SMN2 | |
| SCHEMBL1572680 | 0.91 | APP (1.00) | APPGLAGAASULT1A1 | |
| SCHEMBL13806279 | 0.91 | APP (1.00) | APPGLAGAASULT1A1 | |
| SCHEMBL1977100 | 0.91 | APP (1.00) | APPGLAGAASULT1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208066-A1 | ER-beta-selective ligands | BARLAAM BERNARD | 2007-09-06 | — | — | US | disclosed |
| US-20070208066-A1 | ER-beta-selective ligands | BARLAAM BERNARD | 2007-09-06 | — | — | US | disclosed |
| US-20070208066-A1 | ER-beta-selective ligands | BARLAAM BERNARD | 2007-09-06 | — | — | US | disclosed |
| US-20060111408-A1 | Therapeutic benzothiazole compounds | BARLAAM BERNARD | 2006-05-25 | — | — | US | disclosed |
| US-7045539-B2 | Therapeutic benzoxazole compounds | ASTRAZENECA AB (SE) | 2006-05-16 | — | — | US | disclosed |
| US-20040102435-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | disclosed |
| EP-1345914-A1 | THERAPEUTIC COMPOUNDS | AstraZeneca AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002051821-A1 | THERAPEUTIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-04 | — | — | WO | disclosed |
| EP-0483502-B1 | High temperature resistant benzothiazol-groups containing polyarylether | BASF AG (DE) | 1995-11-22 | — | — | EP | disclosed |
| US-5227454-A | HIGH TEMPERATURE RESISTANT, BENZOTHIAZOLE-CONTAINING POLYARYL ETHERS | BASF AKTIENGESELLSCHAFT (DE) | 1993-07-13 | — | — | US | disclosed |
| EP-0483502-A1 | High temperature resistant benzothiazol-groups containing polyarylether | BASF Aktiengesellschaft (DE) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102435-A1 | Therapeutic compounds | ESRRA, ESRRG, ESR2 | APP 277/4885GLA 151/4885GAA 2669/4885 |
| US-20070208066-A1 | ER-beta-selective ligands | ESR2, ESRRG, ESRRA | APP 195/4885GLA 365/4885GAA 3422/4885 |
| US-20060111408-A1 | Therapeutic benzothiazole compounds | ESR1, ESR2, ESRRG | APP 277/4885GLA 788/4885GAA 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.